ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07528014

Acronym

ATLAS-1

Enrollment

5000

Registered

2026-04-14

Start date

2026-03-25

Completion date

2037-03-01

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressed Mood

Keywords

Depression, transcranial magnetic stimulation (TMS), accelerated TMS, SAINT, Spravato, esketamine, Treatment-resistant depression (TRD), Major depressive disorder (MDD)

Brief summary

This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults (≥18 years) of any gender identity presenting for care with a depressed mood. * Prescribed treatment with esketamine, conventional TMS, or SAINT as part of standard clinical care. * Able to provide informed consent and comply with all study requirements.

Exclusion criteria

* Any condition deemed by the investigator to preclude safe participation in study assessments.

Design outcomes

Primary

Measure	Time frame	Description
Patient Health Questionnaire 9-item (PHQ-9)	Pre-treatment, Post-treatment, 2 weeks posttreatment, and Monthly post-treatment for 12 months	The Patient Health Questionnaire (PHQ-9) is a 9-item multipurpose self-report instrument for screening, diagnosing, monitoring and measuring the severity of depression.

Countries

United States

Outcome results